These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23226042)

  • 1. Ofatumumab: a novel monoclonal anti-CD20 antibody.
    Lin TS
    Pharmgenomics Pers Med; 2010; 3():51-9. PubMed ID: 23226042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
    Ge X; Wu L; Hu W; Fernandes S; Wang C; Li X; Brown JR; Qin X
    Clin Cancer Res; 2011 Nov; 17(21):6702-11. PubMed ID: 21918174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.
    O'Brien S; Osterborg A
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):361-8. PubMed ID: 21030349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies.
    Castillo J; Perez K
    J Blood Med; 2010; 1():1-8. PubMed ID: 22282677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of ofatumumab in treatment of chronic lymphocytic leukemia.
    Veliz M; Pinilla-Ibarz J
    J Blood Med; 2011; 2():71-7. PubMed ID: 22287865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ofatumumab, a human anti-CD20 monoclonal antibody.
    Osterborg A
    Expert Opin Biol Ther; 2010 Mar; 10(3):439-49. PubMed ID: 20109133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
    Reagan JL; Castillo JJ
    Future Oncol; 2014 May; 10(7):1147-55. PubMed ID: 24947256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
    Reagan JL; Castillo JJ
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ofatumumab for the treatment of chronic lymphocytic leukemia.
    Grosicki S
    Expert Rev Hematol; 2015 Jun; 8(3):265-72. PubMed ID: 25882470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.
    Nightingale G
    Ann Pharmacother; 2011 Oct; 45(10):1248-55. PubMed ID: 21896924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use.
    Gravanis I; Ersbøll J; Skovlund E; Abadie E; Marty M; Pignatti F
    Oncologist; 2010; 15(12):1335-43. PubMed ID: 21156732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments in the management of chronic lymphocytic leukemia: role of ofatumumab.
    Laurenti L; Innocenti I; Autore F; Sica S; Efremov DG
    Onco Targets Ther; 2016; 9():421-9. PubMed ID: 26855591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.
    Barth MJ; Czuczman MS
    Future Oncol; 2013 Dec; 9(12):1829-39. PubMed ID: 24295413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells.
    Hörl S; Banki Z; Huber G; Ejaz A; Müllauer B; Willenbacher E; Steurer M; Stoiber H
    Haematologica; 2013 Dec; 98(12):1939-47. PubMed ID: 23850806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
    Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
    Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
    Cheson BD
    J Clin Oncol; 2010 Jul; 28(21):3525-30. PubMed ID: 20458041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
    Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
    Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
    Czuczman MS; Gregory SA
    Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells.
    Mamidi S; Höne S; Teufel C; Sellner L; Zenz T; Kirschfink M
    Oncoimmunology; 2015 Mar; 4(3):e979688. PubMed ID: 25949896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ofatumumab.
    Sanford M; McCormack PL
    Drugs; 2010 May; 70(8):1013-9. PubMed ID: 20481657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.